Kennedy Capital Management Inc. purchased a new position in shares of Cryolife Inc (NYSE:CRY) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 150,847 shares of the medical equipment provider’s stock, valued at approximately $2,889,000. Kennedy Capital Management Inc. owned about 0.45% of Cryolife at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in CRY. State Street Corp boosted its stake in shares of Cryolife by 5.2% during the 2nd quarter. State Street Corp now owns 758,840 shares of the medical equipment provider’s stock worth $15,143,000 after purchasing an additional 37,279 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Cryolife by 4.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 25,737 shares of the medical equipment provider’s stock worth $513,000 after purchasing an additional 1,054 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Cryolife during the 3rd quarter worth about $259,000. Prudential Financial Inc. boosted its stake in shares of Cryolife by 51.6% during the 3rd quarter. Prudential Financial Inc. now owns 133,863 shares of the medical equipment provider’s stock worth $3,039,000 after purchasing an additional 45,580 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Cryolife by 21.0% during the 3rd quarter. Principal Financial Group Inc. now owns 258,323 shares of the medical equipment provider’s stock worth $5,864,000 after purchasing an additional 44,777 shares during the last quarter. 73.99% of the stock is currently owned by institutional investors.
Several equities research analysts have issued reports on CRY shares. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 price target (up from $25.00) on shares of Cryolife in a research note on Friday, March 9th. Northland Securities reissued a “buy” rating and issued a $23.50 target price on shares of Cryolife in a research report on Thursday, March 8th. ValuEngine cut shares of Cryolife from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Finally, Zacks Investment Research raised shares of Cryolife from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Three research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $25.83.
Cryolife (NYSE:CRY) last released its earnings results on Wednesday, March 7th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.11. Cryolife had a net margin of 1.95% and a return on equity of 5.92%. The business had revenue of $52.80 million for the quarter, compared to analysts’ expectations of $48.40 million. During the same period last year, the company earned $0.09 earnings per share. The company’s quarterly revenue was up 17.3% on a year-over-year basis. analysts anticipate that Cryolife Inc will post 0.09 EPS for the current fiscal year.
In other Cryolife news, Director C Elkins Ronald sold 2,000 shares of Cryolife stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $22.00, for a total transaction of $44,000.00. Following the transaction, the director now directly owns 97,849 shares of the company’s stock, valued at $2,152,678. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 6.00% of the company’s stock.
Cryolife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.